Claims for Patent: 8,318,707

Summary for Patent: 8,318,707

Title:	Administration of (S)-roscovitine for protection against and/or treatment of neurological diseases
Abstract:	The present invention relates to the use of 6-(benzyl-amino)-2(S)-[[1-(hydroxymethyl) propyl]amino]-9-isopropylpurine) or at least one of its pharmaceutical acceptable salts for manufacturing a medication intended for the prevention and/or treatment of neurological diseases, in particular associated with neurological lesions.
Inventor(s):	Timsit; Serge (Brest, FR), Menn; Benedicte (Marseilles, FR), Meijer; Laurent (Roscoff, FR)
Assignee:	Neurokin (Marseilles, FR)
Application Number:	12/225,834
Patent Claims:	1. A method for protecting against and/or treating neurological diseases associated with excitotoxic neurological lesions, comprising administering to a subject in need thereof a pharmaceutically effective amount of a composition comprising roscovitine in an enantiomeric excess of greater than or equal to 90% of 6-(benzyl-amino)-2(S)-[[1-(hydroxymethyl)propyl]amino]-9-isopropylpurine) or at least one of its pharmaceutical acceptable salts. 2. The method of claim 1, wherein the neurological diseases are chronic or acute neurological diseases. 3. The method of claim 2, wherein the acute neurological disease is epilepsy; status epilepticus; stroke; cerebral haemorrhages; cerebral hypoxia during cardiac arrests; cranial traumatisms; or neurological diseases causing focal and/or global cerebral hypoxia. 4. The method of claim 3, wherein the cerebral haemorrhages are associated with the use of a thrombolytic agent. 5. The method of claim 4, wherein the thrombolytic agent is a tissue plasminogen activator. 6. The method of claim 1, wherein the neurological diseases are neurodegenerative diseases. 7. The method of claim 6, wherein the neurodegenerative diseases comprise diseases with an extrapyramidal syndrome and dementias. 8. The method of claim 6, wherein the neurodegenerative diseases comprise Parkinson's disease, progressive supranuclear paralysis (Steel-Richardson and Olzewski syndromes), multiple system atrophy, striatonigral degeneration, Alzheimer's disease, vascular dementias, Lewy body disease, fronto-temporal dementias, cortico-basal degeneration, Huntington's chorea, amyotrophic lateral sclerosis and Creutzfeld-Jakob disease. 9. The method of claim 1, wherein the roscovitine or at least one of its pharmaceutical acceptable salts is administered in combination with at least one anti-neurodegenerative agent. 10. The method of claim 9, wherein the anti-neurodegenerative agent is donepezil, selegiline, rivastigmine, galantamine, memantine or riluzole. 11. The method of claim 1, wherein the roscovitine or at least one of its pharmaceutical acceptable salts is administered in combination with at least one thrombolytic agent. 12. The method of claim 11, wherein the thrombolytic agent is a tissue plasminogen activator, a streptokinase, urokinase or desmoteplase. 13. The method of claim 1, wherein or at least one of its pharmaceutical acceptable salts is administered in combination with at least one platelet aggregation inhibiting agent. 14. The method of claim 13, wherein the platelet aggregation inhibiting agent is aspirin, ticlopidine, clopidogrel, persantine, abciximab or flurbiprofen. 15. The method of claim 1, wherein the roscovitine or at least one of its pharmaceutical acceptable salts is administered by oral, rectal, cutaneous, pulmonary, nasal, sublingual or parenteral administration. 16. The method of claim 15, wherein the administration is intradermic, subcutaneous, intramuscular, intravenous, intra-arterial, intrarachidian, intra-articular, intrapleural or intraperitoneal administration. 17. The method of claim 1, wherein the roscovitine or at least one of its pharmaceutical acceptable salts is administered in the form of a tablet, capsule, pill, syrup, suspension, solution, powder, granule, emulsion, microsphere, injectable solution, sublingual spray or skin patch. 18. The method of claim 1, wherein the pharmaceutical composition comprises from 100 mg to 5 g of the roscovitine or at least one of its pharmaceutical acceptable salts per unit dose. 19. The method of claim 18, wherein the pharmaceutical composition comprises from 100 mg to 2 g of the roscovitine or at least one of its pharmaceutical acceptable salts per unit dose. 20. The method of claim 1, wherein the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.

Details for Patent 8,318,707

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Microbix Biosystems Inc.	KINLYTIC	urokinase	For Injection	021846	01/16/1978		2026-03-30
Janssen Biotech, Inc.	REOPRO	abciximab	Injection	103575	12/22/1994		2026-03-30